Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

Figures & data

Figure 1 PRISMA diagram for SLR.

Abbreviations: ABRs, annualized bleed rates; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method; SLR, systematic literature review.

Figure 2 ABRs for BAY 81-8973 (1-year) vs rAHF-PFM.

Note: Data from Valentino et al.¹⁷
Abbreviations: ABRs, annualized bleed rates; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.

Figure 3 ABRs for BAY 81-8973 (1-year) vs rAHF-PFM.

Notes: *P<0.05. Data from Tarantino et al.¹⁶
Abbreviations: ABRs, annualized bleed rates; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.

Table 1 Outcomes for BAY 81-8973 (first 6-month) vs rAHF-PFM

Outcomes	Before matching			After matching
	BAY 81-8973	rAHF-PFM	Difference	BAY 81-8973	rAHF-PFM	Difference
	(N=121)	(N=107)		(N=121)	(N=107)
Patients with zero bleeds, %	36	30	6	38	30	8
ABR, mean (SD)
All bleeds	5.2 (7.3)	6.3 (7.3)	−1.1	5.4 (7.7)	6.3 (7.3)	−0.9
Spontaneous bleeds	3.6 (6.4)	4.1 (6.4)	−0.5	3.0 (5.6)	4.1 (6.4)	−1.1
Trauma bleeds	1.4 (3.7)	4.7 (3.7)	−3.3*	2.3 (5.4)	4.7 (3.7)	−2.4*

Notes:

* P<0.05. Data from Tarantino et al.¹⁶

Abbreviations: ABR, annualized bleed rate; SD, standard deviation.

Figure 4 ABRs for BAY 81-8973 (1-year) vs turoctocog alfa.

Notes: *P<0.05. Data from Lentz et al.¹⁸
Abbreviation: ABRs, annualized bleed rates.

Table 2 Outcomes for BAY 81-8973 (first 6-month) vs turoctocog alfa

Outcome	Before matching			After matching
	BAY 81-8973	Turoctocog alfa	Difference	BAY 81-8973	Turoctocog alfa	Difference
	(N=121)	(N=150)		(N=121)	(N=150)
Patients with zero bleeds, %	36	30	6	37	30	7
ABR, mean (SD)
All bleeds	5.2 (7.3)	6.5 (2.5)	−1.3	5.1 (7.1)	6.5 (2.5)	−1.4*
Spontaneous bleeds	3.6 (6.4)	4.3 (2.1)	−0.7	3.3 (6.0)	4.3 (2.1)	−1.0
Trauma bleeds	1.4 (3.7)	1.6 (1.3)	−0.2	1.6 (4.0)	1.6 (1.3)	0.0

Notes:

* P<0.05. Data from Lentz et al.¹⁸

Abbreviations: ABR, annualized bleed rate; SD, standard deviation.

ValentinoLAMamonovVHellmannAA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementJ Thromb Haemost20121035936722212248

 PubMed Web of Science ®Google Scholar

TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia20041042843715357767

 PubMed Web of Science ®Google Scholar

LentzSRMisgavMOzeloMResults from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacyHaemophilia20131969169723647704

 PubMed Web of Science ®Google Scholar